Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Allergan Inc
Allergan Inc And Baylor College Of Medicine
Allergan Inc_20100107
Allergan Inc_20100121
Allergan Inc_20131212
Allergan Inc_20100114

Allergan Inc patents


Recent patent applications related to Allergan Inc. Allergan Inc is listed as an Agent/Assignee. Note: Allergan Inc may have other listings under different names/spellings. We're not affiliated with Allergan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Allergan Inc-related inventors


 new patent  Adipose tissue combinations, devices, and uses therof

Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction.... Allergan Inc

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present... Allergan Inc

Methods for alleviating histamine-independent pruritus using neurotoxins

Methods for treating, reducing the occurrence or preventing a histamine-independent pruritic itch using a clostridial toxin derivative are provided herein. In some aspects, the clostridial toxin derivative reduces the itch intensity or duration without affecting thermal or pain sensitivity.... Allergan Inc

Degradable clostridial toxins

The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.... Allergan Inc

Soft filled prosthesis shell with variable texture

A soft prosthetic implant, such as a silicone breast implant, is provided. The implant has a variety of different surfaces, for example, different textures, located on different areas of the outer surface of the implant.... Allergan Inc

Method of enhancing hair growth

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or... Allergan Inc

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.... Allergan Inc

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.... Allergan Inc

Dual plane breast implant

A soft breast prosthesis is provided, the prosthesis having a surface configuration advantageous for dual plane placement of the prosthesis in a breast.... Allergan Inc

Cyclosporin derivatives wherein the mebmt sidechain has been cyclized

The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions,... Allergan Inc

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.... Allergan Inc

Fixed dose combination of brimonidine and timolol

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.... Allergan Inc

Methods of providing therapeutic effects using cyclosporin components

Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the... Allergan Inc

Suture line administration technique using botulinum toxins

The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon... Allergan Inc

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.... Allergan Inc

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.... Allergan Inc

Methods for fat reduction

Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.... Allergan Inc

Non-protein clostridial toxin compositions

Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid... Allergan Inc

Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.... Allergan Inc

Method of manufacturing coated beads

The present specification discloses methods of making porogen compositions, methods of making polymer-coated beads, and methods of making implantable devices that use polymer-coated beads.... Allergan Inc

Complement factor bb antibodies

The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the... Allergan Inc

Stabilization of therapeutic agents to facilitate administration

The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated C. botulinum carrier complex is provided, where the carrier complex lacks a native neurotoxin subunit.... Allergan Inc

Self-emulsifying drug delivery (sedds) for ophthalmic drug delivery

Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs.... Allergan Inc

Method of treating conditions with kinase inhibitors

or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Allergan Inc

Injection paradigm for administration of botulinum toxins

Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin... Allergan Inc

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.... Allergan Inc

Compositions containing alpha-2-adrenergic agonist components

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.... Allergan Inc

Ophthalmic compositions and methods for treating eyes

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.... Allergan Inc

Hypotensive lipid-containing biodegradable intraocular implants and related implants

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Allergan Inc

Implants and methods for treating inflammation-mediated conditions of the eye

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodihle polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration... Allergan Inc

Treatment of psychological trauma

The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.... Allergan Inc

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency... Allergan Inc

Joint fat pad formulations, and methods of use thereof

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint... Allergan Inc

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency... Allergan Inc

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.... Allergan Inc

11/30/17 / #20170341949

Production of rounded salt particles

The present disclosure generally relates to methods of preparing spherical salt particles for industrial, medical, and other uses. The methods can include combining the angular salt particles with a quantity of finishing media, for example, into a receptacle. Thereafter, the angular salt particles and the finishing media can be moved... Allergan Inc

11/30/17 / #20170342395

Animal product free system and process for purifying a botulinum toxin

Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.... Allergan Inc

11/16/17 / #20170327810

Fusion proteins and methods for treating, preventing or ameliorating pain

A single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site at which site the fusion protein is cleavable by a protease; a translocation domain capable of translocating... Allergan Inc

11/16/17 / #20170327811

Process and system for obtaining botulinum neurotoxin

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.... Allergan Inc

11/09/17 / #20170320897

Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.... Allergan Inc

10/26/17 / #20170306007

Complement component c5 antibodies

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure... Allergan Inc

10/19/17 / #20170298050

Ester prodrugs of gamma-lactams and their use

Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.... Allergan Inc

10/12/17 / #20170290652

Device and making a variable surface breast implant

Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom.... Allergan Inc

10/12/17 / #20170290987

Aspiration and injection device

An aspiration and injection device is provided that can allow for ergonomic, safe, and precise aspiration of a target site and ejection of a medicament to the target site. The device can include a syringe barrel, a flange extender couplable to the barrel, and plunger that can be engaged by... Allergan Inc

10/05/17 / #20170283487

Immuno-based botulinum toxin serotype a activity assays

The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A... Allergan Inc

09/21/17 / #20170266138

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.... Allergan Inc

09/21/17 / #20170266201

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a... Allergan Inc

09/21/17 / #20170266344

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.... Allergan Inc

09/14/17 / #20170258878

Bladder injeciton paradigm for administration of botulinum toxins

Methods for treating a bladder dysfunction by injecting a clostridial derivative to a target site below the bladder midline are described.... Allergan Inc

09/07/17 / #20170256010

Patent alert system

A computerized publication system comprising an automated alert generation platform for use in monitoring patents or other documents in the public domain, combined with a subscription management module.... Allergan Inc

08/31/17 / #20170248602

Immuno-based retargeted endopeptidase activity assays

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.... Allergan Inc

08/10/17 / #20170224786

Botulinum toxin compositions

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.... Allergan Inc

08/10/17 / #20170224873

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.... Allergan Inc

08/10/17 / #20170226094

Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders... Allergan Inc

08/03/17 / #20170216326

Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).... Allergan Inc

08/03/17 / #20170216414

Dermal filler

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.... Allergan Inc

08/03/17 / #20170218334

Cells useful for immuno-based botulinum toxin serotype a activity assays

The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.... Allergan Inc

07/27/17 / #20170209532

Two part formulation system for ophthalmic delivery

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the... Allergan Inc

07/06/17 / #20170189412

Androgen composition for treating an opthalmic condition

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.... Allergan Inc

06/29/17 / #20170182028

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically... Allergan Inc

06/29/17 / #20170182062

4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid... Allergan Inc

06/29/17 / #20170182064

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Allergan Inc

06/29/17 / #20170183293

Novel ep4 agonists as therapeutic compounds

Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.... Allergan Inc

06/29/17 / #20170183298

Carbamoyl hydrazine derivatives as formyl peptide modulators

The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the FPR receptor.... Allergan Inc

Patent Packs
06/22/17 / #20170172957

D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders

The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.... Allergan Inc

06/22/17 / #20170172959

D-serine for the treatment of visual system disorders

The present invention relates to therapeutic methods using pharmaceutical compositions comprising one or a combination of co-agonists at the N-methyl-D-aspartate receptor for the treatment of visual system disorders.... Allergan Inc

06/22/17 / #20170172982

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.... Allergan Inc

06/22/17 / #20170172983

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.... Allergan Inc

06/22/17 / #20170173123

Botulinum toxin treatments of neurological and neuropsychiatric disorders

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve,... Allergan Inc

06/22/17 / #20170173318

Multi-site injection system

A multi-site injection system includes a plurality of medicament delivering needles/microprotrusions, a needle/microprotrusion support, a supply of medicament, and a mechanism for providing the medicament to the plurality of needles/microprotrusions in order to effect delivery into a stratum corneum of a user.... Allergan Inc

06/22/17 / #20170174664

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Allergan Inc

06/22/17 / #20170174858

Porogen compositions, methods of making and uses

Provided are porogen compositions and methods of using such porogen compositions in the manufacture of porous materials, for example, porous silicone elastomers. The porogens generally include comprising a core material and shell material different from the core material. The porogens can be used to form a scaffold for making a... Allergan Inc

06/08/17 / #20170157207

Method of treating conditions of the eye with an anti-vegf darpin

Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to... Allergan Inc

06/01/17 / #20170151217

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of... Allergan Inc

06/01/17 / #20170151261

Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations

A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof,... Allergan Inc

06/01/17 / #20170151367

Dry dermal filler compositions and methods of reconstitution

Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.... Allergan Inc

06/01/17 / #20170152224

Novel prostamides for the treatment of glaucoma and related diseases

Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.... Allergan Inc

05/25/17 / #20170143728

Method of treating conditions with kinase inhibitors

or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Allergan Inc

05/25/17 / #20170143733

Compounds and methods for skin repair

The disclosure provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one mixed EP2/EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such... Allergan Inc

Patent Packs
05/25/17 / #20170143792

Cyclosporin compositions

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.... Allergan Inc

05/25/17 / #20170144999

Therapeutic substituted cyclopentanes

Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—,... Allergan Inc

05/18/17 / #20170136106

Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence

Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (NDO) and for reducing need for or frequency of clean intermittent catherization (CIC) by injecting a clostridial derivative to the bladder of a patient are disclosed.... Allergan Inc

05/18/17 / #20170136145

Dermal filler compositions including antioxidants

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.... Allergan Inc

05/18/17 / #20170137423

Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response

Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.... Allergan Inc

05/11/17 / #20170128552

Methods for treating headache

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the... Allergan Inc

05/04/17 / #20170119703

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.... Allergan Inc

05/04/17 / #20170119737

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.... Allergan Inc

04/27/17 / #20170112853

Hypotensive lipid and timolol compositions and methods of using same

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional... Allergan Inc

04/20/17 / #20170107210

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.... Allergan Inc

04/20/17 / #20170107279

Heavy chain only antibodies to ang-2

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.... Allergan Inc

04/13/17 / #20170100334

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Allergan Inc

04/06/17 / #20170096401

Imidazole derivatives as formyl peptide receptor modulators

The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.... Allergan Inc

04/06/17 / #20170096419

Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders... Allergan Inc

04/06/17 / #20170096423

Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the FP, DP, EP1, EP4, IP, DP1, FP and TP prostaglandin (PG) receptors thereby providing a general anti-inflammatory response.... Allergan Inc

03/30/17 / #20170087102

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency... Allergan Inc

03/30/17 / #20170087163

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. In another aspect, there are provided substantially... Allergan Inc

03/30/17 / #20170087273

Bioerodible matrix for tissue involvement

Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a... Allergan Inc

03/23/17 / #20170079956

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.... Allergan Inc

03/23/17 / #20170080154

Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form

Described herein are injection devices capable of automatically injecting substances into the soft tissue of a patient. The devices can inject low to high viscosity materials at predetermined, user selected injection rates, allowing the operator more control than a traditional syringe. The devices can allow mixing of more than one... Allergan Inc

03/23/17 / #20170081304

Quaternary ammonium alkyl esters as stable prodrugs

Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.... Allergan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Allergan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###